Anglo-Swedish pharmaceuticals giant AstraZeneca on Thursday agreed to buy French biotech specialist Amolyt Pharma for about $1 billion, expanding further into the field of rare drugs.
This article was originally published on this website.
AstraZeneca buys French biotech firm Amolyt for $1 bn
